The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United ...

Key Points Revenue (GAAP) reached $124.1 million, surpassing the $115.5 million GAAP estimate and rising 29.7% year-over-year. Non-GAAP earnings per share improved to ($0.24), beating expectations and ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...

This news is for Australian Media only Eflornithine is now reimbursed by the government under Australia's Pharmaceutical ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

On July 31, Russia’s Defense Ministry announced that its forces had taken control of the Ukrainian city of Chasiv Yar, near ...

The Company will reconvene its Annual General and Special Meeting of shareholders (the “Reconvened Meeting”) on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on the appointment of EY and the ...

The 2025 World Bronchiectasis Conference highlighted new research on bronchiectasis and NTM - plus an emerging ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.